@article{oai:repo.qst.go.jp:00077577,
 author = {Yasuda, Shigeo and Katou, Hirotoshi and Imada, Hiroshi and Isozaki, Yuka and Kasuya, Goro and Makishima, Hirokazu and Tsuji, Hiroshi and Ebner, Daniel and Yamada, Shigeru and Kamada, Tadashi and Tsujii, Hirohiko and Kato, Naoya and Miyazaki, Masaru and Yasuda, Shigeo and Katou, Hirotoshi and Imada, Hiroshi and Isozaki, Yuka and Kasuya, Goro and Makishima, Hirokazu and Tsuji, Hiroshi and Ebner, Daniel and Yamada, Shigeru and Kamada, Tadashi and Tsujii, Hirohiko and Kato, Naoya and Miyazaki, Masaru},
 issue = {2},
 journal = {Advances in Radiation Oncology},
 month = {Sep},
 note = {Purpose: Carbon ion beams have several physical and biological advantages compared with conventional radiation for cancer therapy. The objective of this study is to evaluate the safety and effectiveness of 2-fraction carbon ion radiation therapy (CIRT) in patients with hepatocellular carcinoma (HCC).
Methods and Materials: Between December 2008 and March 2013, 57 patients with localized HCC were treated with CIRT at a total dose of 45 Gy (relative biological effectiveness) in 2 fractions and retrospectively analyzed after long-term observation. The main endpoints of this study were treatment-related toxicity and local tumor control. Toxicity was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Changes in the Child-Pugh score from before to after CIRT were also examined to evaluate hepatic toxicity. Local control was defined as no progression of the irradiated lesion according to the modified Response Evaluation Criteria in Solid Tumors.
Results: The median age of the patients was 75 years (range, 49-89 years). Of these patients, 41 had a newly diagnosed lesion, and 16 had residual or recurrent lesions after previous treatments.},
 pages = {196--203},
 title = {Long-Term Results of High-Dose 2-Fraction Carbon Ion Radiation Therapy for Hepatocellular Carcinoma},
 volume = {5},
 year = {2019}
}